Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 2 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Results 1 - 10 of 10

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 1/2/2016 9:23:53 PM : Outperform Start Price: $0.51 CYCC Score: -30.86

My God, is the SEAMLESS trial still running? This pointless excursion began all the way back at the beginning of 2011 and is still lumbering along despite failing an interim futility analysis in December 2014. That's right! The trial already failed. That failure came on the heels of numerous other failures of the sapacitabine/seliciclib pipeline and exactly zero successes. Paying yourself salary while continuing failed trials seems to be a rather unimaginative way of looting the remaining cash in company coffers, but managing small cap biotech companies seems to confer impunity these days.

So why a green thumb? Cash was 23M at the end of Q3 and the current market cap is 17M. Recent quarterly burn has been about 4M. There's always a chance enough people will be fooled by optimistic pronouncements about a possible upset shocker for SEAMLESS that the share price will drift up a little before the final, permanent failure is announced in the first half of this year. Hell, it just happened with Repros and their doomed PDUFA. If not, Cyclacel might be a sweet bounce play if SEAMLESS failure knocks the cap under 12M. Of course, the bounce was dead in 2015 but eventually it will come back into style and early adopters will reap the lion's share of returns. Perhaps even my stable of sinking dookies will show some new life in the new year.

Recs

0
Member Avatar oscillation (23.41) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $0.74 CYCC Score: -46.15

nev

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $3.85 CYCC Score: -94.26

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (54.27) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $5.50 CYCC Score: -117.34

Looks good IMO

Recs

0
Member Avatar stainsolution (< 20) Submitted: 4/9/2012 9:52:19 AM : Outperform Start Price: $4.55 CYCC Score: -128.47

Small Cancer/Bio

Recs

0
Member Avatar RBuskey106 (48.93) Submitted: 3/21/2012 8:23:14 PM : Outperform Start Price: $4.40 CYCC Score: -125.71

Small cancer bio

Recs

0
Member Avatar nwarrior (< 20) Submitted: 7/27/2011 2:55:42 AM : Outperform Start Price: $8.26 CYCC Score: -137.00

This stock is poised to rise, already near it's 52 Week low. With a high insider net holding volume and low debt, this is an investment with great potential.

Recs

0
Member Avatar rwaddoups (< 20) Submitted: 1/3/2011 1:22:52 PM : Outperform Start Price: $10.50 CYCC Score: -143.56

yes

Recs

0
Member Avatar verbatum (< 20) Submitted: 10/5/2010 8:03:18 PM : Outperform Start Price: $11.34 CYCC Score: -158.13

Great Pipeline,Great PHASE II, Entering PHASE III, Shelf registered, Orphan Designation

Recs

0
Member Avatar imrhh (< 20) Submitted: 5/5/2007 11:23:19 PM : Underperform Start Price: $54.60 CYCC Score: +130.20

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy, but I can't see much of a future in this stock unless it is bought by one of the bigger companies.

Results 1 - 10 of 10

Featured Broker Partners